We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Rare Genetic Diseases Share Molecular Switch

By Biotechdaily staff writers
Posted on 09 Jun 2002
A new study explains part of the cellular basis of Fanconi anemia (FA) and also establishes a molecular link to a clinically distinct genetic disease, ataxia telangiectasia (AT). More...
Fanconi anemia (FA) is an inherited genetic disorder characterized by birth defects, progressive bone marrow failure, and an extremely high risk of developing leukemia or other forms of cancer. The study was published in the May 17, 2002, issue of Cell.

Cells from individuals with FA are hypersensitive to chemicals that damage DNA, indicating a defect in DNA repair mechanisms. Some FA subtypes also exhibit an increased sensitivity to DNA damage induced by ionizing radiation. This type of sensitivity is also found in other human syndromes including AT.

It was known that chemically induced damage to DNA modifies the Fanconi anemia protein, FANCD2, in different ways, depending on the nature of the DNA-damaging agent. Researchers at Harvard Medical School (Boston MA, USA) led by Dr. Alan D'Andrea now report that FANCD2 serves as a link between the chemical- and ionizing radiation-induced DNA damage response pathways.

Exposure of normal cells to ionizing radiation causes phosphorylation of the FANCD2 protein that is mediated by the product of the ATM gene (the gene responsible for phosphorylation in AT). This modification induces FANCD2 to stimulate a DNA repair pathway separate from that used to respond to chemical-induced damage. This discovery explains the common sensitivity to radiation shared by these distinct genetic disorders.

The authors propose that FANCD2 functions as a kind of molecular switch, and that depending on the modification it receives, it activates different DNA repair pathways. "Although FA and AT are rare diseases, recent studies have shown that breast cancer and other commonly occurring tumors are caused by acquired defects in these DNA repair pathways,” explains Dr. D'Andrea.



Related Links:
Harvard University

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.